Literature DB >> 1721315

Comparative in vitro studies on the immunosuppressive activities of mycophenolic acid, bredinin, FK 506, cyclosporine, and rapamycin.

A Zeevi1, M Woan, G Z Yao, R Venkataramanan, S Todo, T E Starzl, R J Duquesnoy.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1721315      PMCID： PMC3018875     

Source DB:  PubMed          Journal:  Transplant Proc        ISSN： 0041-1345            Impact factor:   1.066


× No keyword cloud information.
  10 in total

1.  Studies on immunosuppression with low-dose cyclosporine combined with mizoribine in experimental and clinical cadaveric renal allotransplantation.

Authors:  T Osakabe; H Uchida; Y Masaki; K Yokota; K Sato; Y Nakayama; M Ohkubo; K Kumano; T Endo; K Watanabe
Journal:  Transplant Proc       Date:  1989-02       Impact factor: 1.066

2.  Synergistically enhanced immunosuppressive effect by combined use of cyclosporine and mizoribine.

Authors:  H Amemiya; S Suzuki; H Watanabe; R Hayashi; S Niiya
Journal:  Transplant Proc       Date:  1989-02       Impact factor: 1.066

3.  Studies on bredinin. I. Isolation, characterization and biological properties.

Authors:  K Mizuno; M Tsujino; M Takada; M Hayashi; K Atsumi
Journal:  J Antibiot (Tokyo)       Date:  1974-10       Impact factor: 2.649

Review 4.  The pharmacology and clinical use of methotrexate.

Authors:  J Jolivet; K H Cowan; G A Curt; N J Clendeninn; B A Chabner
Journal:  N Engl J Med       Date:  1983-11-03       Impact factor: 91.245

5.  Inhibition of T-lymphocyte activation by the immunosuppressive drug FK-506.

Authors:  J E Kay; C R Benzie; M R Goodier; C J Wick; S E Doe
Journal:  Immunology       Date:  1989-08       Impact factor: 7.397

6.  Cyclosporine, FK506, and rapamycin. Some effects on early activation events in serum-free, mitogen-stimulated mouse spleen cells.

Authors:  S M Metcalfe; F M Richards
Journal:  Transplantation       Date:  1990-04       Impact factor: 4.939

7.  Organospecific activation of azathioprine in mice: role of liver metabolism in mutation induction.

Authors:  P Hrelia; L Murelli; M Scotti; M Paolini; G Cantelli-Forti
Journal:  Carcinogenesis       Date:  1988-06       Impact factor: 4.944

8.  Lymphocyte-selective cytostatic and immunosuppressive effects of mycophenolic acid in vitro: role of deoxyguanosine nucleotide depletion.

Authors:  E M Eugui; S J Almquist; C D Muller; A C Allison
Journal:  Scand J Immunol       Date:  1991-02       Impact factor: 3.487

9.  The inhibition of nucleic acid synthesis by mycophenolic acid.

Authors:  T J Franklin; J M Cook
Journal:  Biochem J       Date:  1969-07       Impact factor: 3.857

10.  Guanine ribonucleotide depletion inhibits T cell activation. Mechanism of action of the immunosuppressive drug mizoribine.

Authors:  L A Turka; J Dayton; G Sinclair; C B Thompson; B S Mitchell
Journal:  J Clin Invest       Date:  1991-03       Impact factor: 14.808
  10 in total
  4 in total

1.  Comparative in vitro studies on the immunosuppressive effects of purine and pyrimidine synthesis inhibitors.

Authors:  A Zeevi; G Z Yao; R Venkataramanan; R J Duquesnoy; S Todo; J J Fung; T E Starzl
Journal:  Transplant Proc       Date:  1993-02       Impact factor: 1.066

Review 2.  Mycophenolate mofetil. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in renal transplantation.

Authors:  B Fulton; A Markham
Journal:  Drugs       Date:  1996-02       Impact factor: 9.546

3.  Efficacy of rapamycin and FK 506 in prolonging rat hind limb allograft survival.

Authors:  M J Fealy; W S Umansky; K D Bickel; J J Nino; R E Morris; B H Press
Journal:  Ann Surg       Date:  1994-01       Impact factor: 12.969

4.  Effects of combined administration of FK 506 and the purine biosynthesis inhibitors mizoribine or mycophenolic acid on lymphocyte DNA synthesis and T cell activation molecule expression in human mixed lymphocyte cultures.

Authors:  A W Thomson; J Woo; G Z Yao; S Todo; T E Starzl; A Zeevi
Journal:  Transpl Immunol       Date:  1993       Impact factor: 1.708
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.